Prostate cancer is a prevalent disease in men. It usually begins as androgen-dependent and develops into an androgen-independent phenotype with time. CBG, a known serotonin receptor antagonist, has potential beneficial pharmacological effects on androgen-independent tumour development. It has been proposed that DHEA, the ethanolamide derivative of the polyunsaturated fatty acid DHA, is more potent at inhibiting prostate cancer cell growth and proliferation than its parent compound. The androgen-sensitive LNCaP cell line was used for an in vitro cell viability assay in this project. The focus...